Effectiveness of Stellate Ganglion Block in Patients Diagnosed With Parkinson's Disease: A Randomized Trial

Trial ID: NCT06319625

Interventional - Phase Unknown - Unknown status

The goal of this or clinical trial is to explore efficacy of stellate ganglion block on dysphagia and activities of daily living in patients with Parkinson's disease. The main question it aims to answer are: • Can stellate ganglion block improve the dysphagia and activities of daily living in patients with Parkinson's disease. Participants will be divided into the the control group and observation group evenly. All the patients were provided with routine therapy, while the patients in the observation group were given stellate ganglion block. The swallowing function, and activities of daily living of the two groups of patients before and after treatment were evaluated.

Conditions

• Parkinson Disease

Interventions

• Rehabilitation therapy
• Stellate ganglion block
• Lidocaine hydrochloride
• Placebo injection

Eligibility

Inclusion criteria

• Age \>18 years.
• Meeting the diagnostic criteria for Parkinson's disease developed by the Neurology Branch of the Chinese Medical Association in 2006.
• Diagnosed with dysphagia confirmed by the video fluoroscopic swallowing study.
• Stable vital signs, conscious, able to cooperate with assessment and treatment.

Exclusion criteria

• Dysphagia possibly caused by other reasons, such as cerebrovascular disease, trauma, neuromuscular diseases, malignant diseases of the pharynx and larynx, and digestive tract diseases.
• History of mental diseases or use of antipsychotics.
• Complicated with cognitive impairment or consciousness dysfunction.
• Simultaneously suffering from severe liver, kidney failure, tumors, or hematological diseases.

Sponsor

Copka Sonpashan

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows